Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2021-11-02 Director's Dealing
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Director Dealing
Director's Dealing Classification · 100% confidence The document is an official announcement disseminated via RNS (RNS Number : 0606R) on November 2, 2021. The content explicitly details a 'Director Dealing' transaction where a person closely associated with a Non-Executive Director purchased company shares. This type of insider transaction notification is specifically covered by the 'Director's Dealing' definition. Therefore, the appropriate classification is DIRS.
2021-11-02 English
Group of companies' accounts made up to 2021-04-30
Regulatory Filings
2021-11-02 English
Notice of Annual General Meeting
AGM Information Classification · 98% confidence The document explicitly states 'Notice of Annual General Meeting' and provides the date and time for the AGM. It is a short announcement (4601 characters) that directs the reader to the company website for the full notice, fitting the description of an announcement rather than the full meeting materials. The presence of the RNS Number and the closing statement about RNS distribution confirms it is a regulatory announcement. Since the document is a 'Notice of Annual General Meeting', the most specific code is AGM-R (AGM Information). Although it is an announcement, AGM-R is more specific than RPA or RNS for this content type.
2021-11-01 English
Results for the year ended 30 April 2021
Earnings Release Classification · 99% confidence The document is titled 'Results for the year ended 30 April 2021' and explicitly states it announces 'its final audited financial results for the year ended 30 April 2021 as well as a business update.' It contains detailed financial highlights (Operating Loss, Cash Balance) and extensive operational updates typical of a full annual review. The RNS Number format (6515Q) and the presence of a Chairman's Statement and detailed platform descriptions strongly suggest this is the primary annual filing. Although it is an RNS announcement, the content is the full annual results summary, which aligns best with the Annual Report (10-K) category, as it covers the full fiscal year performance and is not merely a short announcement of publication (Rule 2 does not strictly apply as the document is very long and contains the substance, not just a pointer to the substance). Given the context of UK reporting, this RNS serves as the primary release of the Annual Report information. FY 2021
2021-10-29 English
Extension of CLN Redemption Dates
Regulatory Filings Classification · 98% confidence The document is identified by the header 'RNS Number : 5929Q' and contains contact information for 'RNS, the news service of the London Stock Exchange'. The content announces an 'Extension of Convertible Loan Note Redemption Dates' for Scancell Holdings plc, which is a material corporate event concerning financing/debt structure. This type of announcement, distributed via the Regulatory News Service (RNS), is typically classified as a general regulatory filing or a specific financing update. Since the core subject is the amendment of loan note redemption dates, it strongly relates to capital structure changes. However, the presence of the RNS distribution boilerplate and the nature of the announcement (a specific corporate action update distributed via the regulatory feed) makes 'Regulatory Filings' (RNS) a strong candidate, especially since 'Capital/Financing Update' (CAP) is usually for fundraising or major capital structure changes, and this is an amendment to existing debt. Given the context of RNS distribution for non-standard reports, RNS is the most appropriate general classification for this type of regulatory news release that isn't a formal financial statement or proxy.
2021-10-28 English
New facilities at The Oxford Science Park
Regulatory Filings Classification · 100% confidence The document is identified by the header 'RNS Number : 4445P' and contains a press release format detailing operational news (expansion of R&D facilities at The Oxford Science Park) from Scancell Holdings Plc. The footer explicitly states, 'Reach is a non-regulatory news service,' and the document is distributed via 'RNS' (London Stock Exchange's service). Since this is a general operational announcement that does not fit specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS), and it is a formal announcement distributed through the RNS system, the most appropriate classification is the general regulatory/news announcement fallback category, RNS.
2021-10-19 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.